Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our ...

Bio-Techne (NASDAQ:TECH) reported second-quarter fiscal 2026 results that management said were largely in line with internal ...

Bio-Techne Corporation (NASDAQ:TECH) reported second-quarter fiscal 2026 results that showed steady revenue but stronger ...

Feb 4 (Reuters) - Biotech firm Bio-Techne beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug development. The ...

Bio-Techne tops Q2 EPS and revenue estimates as operating margin jumps 244 bps, even with flat organic sales and a slight ...

Bio-Techne (NASDAQ: TECH) just disclosed its Q2 earnings on Wednesday, February 4, 2026 at 06:30 AM. Here's a brief overview ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

Bio-Techne expands 3D stem cell and organoid culture portfolio with a fully defined synthetic alternative: Minneapolis Tuesday, February 3, 2026, 17:00 Hrs [IST] Bio-Techne Corpor ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) reported flat revenue but improved profitability in its second quarter fiscal 2026 results, with adjusted earnings per share rising to $0.46 compared ...

Find the latest biotech news, including an appointment strengthening the pathway from translational research to new company ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...